合作方迎来跨国巨头20亿美元投资 康方生物依沃西单抗能成为“重磅炸弹”吗?

每日经济新闻
Sep 29

9月29日早间,康方生物在微信公众号上发布消息,阿斯利康以20亿美元认购Summit Therapeutics(以下简称Summit)新发行的可转换优先股,折合每股18.36美元。同时双方围绕PD-1/VEGF双抗依沃西单抗(AK112)与阿斯利康ADC(抗体偶联药物)管线建立临床合作。  依沃西单抗是康方生物的核心产品,Summit2022年获得该药在美国、欧洲、日本等区域的开发与商业化独家权益...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10